Biotech outran healthcare: XBI 1.9%, BBC 2.5% and NBI 0.8% against XLV (0.3%) and the S&P 500's 0.4%. Single names moved hard: Neurocrine closed up about 13% after its Q3, and Madrigal traded about 14% higher premarket on Rezdiffra's quarter.

Chip stocks pulled the S&P 500 out of a three-day losing streak and the Nasdaq 100 up 0.7%: AMD and Broadcom gained about 3%, Micron and Nvidia more than 2%. Apple fell 1.9% on a soft holiday-quarter margin guide and dragged the Dow (0.4%). Brent settled 1.1% lower at $103.60 on reports of progress toward a US-Iran deal, September JOLTS showed openings rising, and the 10-year sat near 4.91% as midterm voting got under way.

Servier's sevasemten (oral fast skeletal myosin inhibitor, bought from Edgewise for $1.55B upfront plus up to $1.1B in milestones) missed the North Star Ambulatory Assessment primary endpoint and all secondaries in the 18-month, 175-patient GRAND CANYON Becker trial. Safety was favourable, and Servier is re-analysing the dataset (release Tue 13:00 GMT).

Why it matters: Servier paid $1.55B in cash in June and closed on 13 July, so it carried the binary risk for less than four months. GRAND CANYON ran 18 months in 175 adults on the North Star Ambulatory Assessment, the endpoint FDA pointed Edgewise to in June 2025 when it refused an accelerated filing on Phase 2 CANYON. That Phase 2 won on creatine kinase, but its NSAA gap was not significant (p=0.16), so the pivotal miss repeats the warning in the earlier data. Edgewise keeps the cash and loses only up to $1.1B of milestones that now look remote. Servier has not said whether the Phase 2 Duchenne work continues, and Becker still has no approved therapy.

Source: STAT

More: Endpoints; Servier; European Biotechnology

Novo Nordisk raised its 2026 outlook for adjusted sales and adjusted operating profit growth to -2% to +2% at CER, from a 0% to 6% decline. Q3 adjusted sales were DKK79.2B vs DKK73.2B expected, and adjusted operating profit was DKK31.7B vs DKK28.4B (release Wed 01:30 ET).

Why it matters: Wegovy pill sales of DKK5.39B (~$810M) beat the DKK4.62B consensus, rose 53% on Q2 and came from about 3.6M US prescriptions in the quarter. US injectable Wegovy fell 13% at CER, so part of the pill's growth is switching, though combined US Wegovy still grew 21%. Q3 also booked a DKK4.6B ziltivekimab impairment after the ZEUS cardiovascular Phase 3 failed in July, and CEO Mike Doustdar told Fierce Novo is still hunting deals to close some of the gaps. The 27% CER jump in adjusted operating profit is flattered by DKK9B of transformation costs in Q3 2025. Lilly raised its outlook last week and Foundayo is taking a growing share of new oral prescriptions, so Q4 becomes a pill-share fight.

Source: Fierce Biotech

More: Reuters; Novo release

Pfizer raised 2026 revenue guidance to $62.0–64.0B (from $60.5–62.5B) and adjusted EPS to $2.95–3.05 (from $2.80–3.00). Q3 revenue was $16.58B, flat operationally and up 7% excluding Comirnaty and Paxlovid; adjusted EPS was $0.87 (Tue pre-open).

Why it matters: The growth is coming from the right lines: Eliquis $2.52B (+25% operational), Padcev $720M (+55%), Nurtec $547M (+33%) and oncology $4.33B (+10%), against Comirnaty at $808M (down 30%) and Paxlovid at $449M (down 63%). Prevnar fell 10% to $1.56B, the soft spot in vaccines. The quarter booked a $3.8B impairment on sigvotatug vedotin after its Phase 3 lung cancer miss, and Pfizer also axed a Phase 2 BMP9-targeted pulmonary arterial hypertension programme and trimmed its obesity pipeline. The EPS range moves up 10 cents at the midpoint while Covid keeps shrinking, which is the mix change the stock has waited for. Shares still slipped about 0.2% early.

Source: Endpoints

More: Fierce Pharma; Fierce Biotech; Pfizer 8-K

Ultragenyx is cutting about 20% of staff (to ~1,000; ~$25M Q4 charges; 2027 R&D below $350M) and ending UX701 in Wilson disease after dose-finding missed its Phase 3 bar; 2026 revenue guidance of $730–760M was reaffirmed (Tue after close). — Endpoints

Sanofi ended the Phase 1 SAR448272 oral STAT6 degrader just two months after it entered the clinic, so Nurix forgoes its milestones and royalties; NRIX fell about 34% after hours, and Nurix says its runway still reaches 2H29 (Tue after close). — Fierce Biotech

Compass said its COMP360 depression filing should be complete within two weeks. — BioSpace

Vertex Q3 revenue rose 12% to $3.44B and guidance moved to $13.15–13.25B; it is de-prioritising zimislecel for VX-017, and the povetacicept IgAN decision is due 30 Nov. — Vertex release

Madrigal said Rezdiffra passed blockbuster pace in MASH; MDGL rose about 14% premarket. — Fierce Pharma

Neurocrine defended Vykat XR after another Prader-Willi patient death and plans a new dosing and safety study. — BioSpace

AbbVie dropped a Phase 2 solid tumour drug over "limited benefit". — Fierce Biotech

Bourla said likely midterm gains by Democrats would not alter MFN pricing deals. — Endpoints

Minghui licensed Japan rights to MHB018A (subcutaneous IGF-1R antibody, Phase 3 thyroid eye disease) to ASKA Pharmaceutical for $110M upfront and up to $330M in milestones. — Endpoints

Thryv Therapeutics raised a $30M Series B led by strategic investor InClin, with existing backers Fonds de solidarité FTQ, Amplitude, Investissement Québec and Lumira, to launch the Phase 2a ASPIRE-HF study of SGK1 inhibitor THRV-1268 in HFrEF (enrolling early 2027); the first Long QT efficacy cohort is fully enrolled, with data in early 2027. — PR Newswire

No notable IPOs or follow-ons since yesterday's edition.

A tumor transcriptomic atlas found early-onset colorectal cancer has distinct stromal and lncRNA features. — Nature Medicine

A phase 2 trial reported encouraging pathological responses with perioperative ivonescimab in resectable NSCLC. — Nature Medicine

Regulatable IL-15 engineered TIL therapy showed preliminary efficacy in checkpoint-resistant advanced melanoma. — Nature Medicine

SER-155 showed a placebo-like safety profile and fewer bloodstream infections in transplant recipients. — Nature Medicine